💊FDA & PHARMA TODAY
Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Initiative
Tokyo, Basking Ridge, NJ, and New York – (April 4, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and DarwinHealth today announced they have entered into a research agreement providing Daiichi Sankyo with exclusive access to DarwinHealth’s proprietary novel cancer target database in order to identify potential new targets for cancer drug development.
DarwinHealth’s proprietary database and technology were created to identify critical mechanisms linked to tumor dependencies and maintenance beyond genetic mutations, and include information on Master Regulators of specific tumor subtypes, as well as direct upstream modulators (both necessary for cancer cell maintenance) across more than 35 tumor and 90 tumor subtypes.
https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006833.html
Takeda Pharmaceutical and DNDi Collaborate to Progress a Potential New Drug for Visceral Leishmaniasis through the R&D Pipeline
Osaka, Japan and Geneva, Switzerland – 5 April, 2018 — Takeda Pharmaceutical Co., Ltd. (TSE: 4502), (“Takeda”) and the Drugs for Neglected Diseases initiative (“DNDi”) today announced that they have signed an agreement to collaborate in conducting preclinical and phase I clinical studies on drug candidate compounds that had been discovered among the aminopyrazole compound class, aimed at developing an innovative drug for the treatment of visceral leishmaniasis (VL).